Industry News


Cytori to Acquire Azaya Platform, Cancer Candidates

2017-01-19 genengnews
Cytori Therapeutics said today it plans to acquire the liposomal nanoparticle technology platform of Azaya Therapeutics for up to $170 million, in a deal designed to expand and complement the buyer’s regenerative medicine operations.

1
share
BRIEF-Cytori to acquire proprietary nanoparticle development platform

2017-01-19 reuters
* Cytori Therapeutics - under terms, Cytori's aggregate commercialization milestone payment obligations to Azaya will not exceed $16.25 million

Can The Uptrend Continue for Penumbra (PEN)?

2017-01-19 zacks
Investors certainly have to be happy with Penumbra Inc (PEN - Free Report) and its short term performance. After all, the stock has jumped by 16.2% in the past 4 weeks, and it is also above its 20 Day Simple Moving Average as well. This is certainly a good trend, but investors are probably asking themselves, can this positive trend continue for PEN?

Vial Adaptors for Reconstitution Drug Market to be Worth US$1.3 Billion by 2024: Reduced Risk of Needlestick Injuries Ups Demand, Notes TMR

2017-01-19 prnewswire
The Global Vial Adaptor for Reconstitution Drug Market is fairly consolidated as top four players hold a leading share in the global market. A report by Transparency Market Research states that West Pharmaceutical Services, Inc., Cardinal Health Inc., Baxter International Inc., and Becton, Dickinson & Company collectively held about 67% in the global market in 2015. These companies are expected to focus on enhancing their product portfolio, expanding their geographical presence, and making strategic acquisitions and mergers to stay ahead of the competition in the coming years.

Cardiovascular Monitoring and Diagnostic Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

2017-01-18 prnewswire
NEW YORK, Jan. 18, 2017 /PRNewswire/ -- This report on the cardiovascular monitoring and diagnostic devices market analyzes the current and future scenario of the global market. Stroke, heart failure, and other prominent cardiovascular diseases are increasing the usage of cardiovascular monitoring and diagnostic devices. Rising geriatric population and unhealthy diet are the major drivers of the global cardiovascular monitoring and diagnostic devices market.

Drug Delivery Technology Market by Route of Administration, Patient Care Setting - Global Forecast to 2021

2017-01-18 prnewswire
NEW YORK, Jan. 18, 2017 /PRNewswire/ -- The drug delivery technology market is projected to reach USD 1,669.40 billion by 2021 from USD 1,179.20 billion in 2016, at a CAGR of 7.2% during the forecast period. Increasing prevalence of chronic diseases, increasing demand for biologics, technological advancements, and new product launches are the factors driving the growth of this market. Whereas, self-administration & home care and rising demand for biosimilars and generic drugs offer significant growth opportunities for players operating in this market.

Allergan's Uterine Fibroids Candidate Positive in Phase III

2017-01-18 zacks
Allergan Plc (AGN - Free Report) and European specialty pharma company Gedeon Richter reported encouraging results from a phase III study on their pipeline candidate, ulipristal acetate, a selective progesterone receptor modulator (SPRM), in women with abnormal bleeding due to uterine fibroids.  

The Cooper Companies: A Good Business, But Investors Should Target A Better Price

2017-01-18 seekingalpha
Cooper steadily has taken market share in contact lenses, and with two major competitors in a bit of disarray, that trend should continue.

Concert Offers Update on Cystic Fibrosis Drug, Stock Down

2017-01-18 zacks
Concert Pharmaceuticals, Inc. (CNCE - Free Report) provided update on the development plan of its next generation CFTR potentiator, CTP-656, for the treatment of cystic fibrosis in the U.S. and Europe. Shares of the company were down approximately 14% on the news.

Orthofix International NV Release: Medtech Announces Resolution Of SEC Investigations

2017-01-18 devicespace
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix International N.V. (NASDAQ:OFIX), a diversified, global medical device company, today announced it has reached final resolutions of previously disclosed Securities and Exchange Commission (SEC) investigations of certain historic accounting matters and of anti-bribery matters in Brazil. The resolutions are on the same material terms as previously disclosed by the Company, and all monetary payments being made to the SEC were accrued in the second and third quarters of 2016 and funded into escrow in the fourth quarter of 2016.

Haemonetics Sets Date For 3rd Quarter Fiscal 2017 Earnings Release: February 6, 2017

2017-01-18 devicespace
BRAINTREE, Mass., Jan. 17, 2017 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) today announced that the Company will publish fiscal year 2017 third quarter financial results at 6:00am Eastern Time on Monday, February 6, 2017. The Company will hold a webcast conference call with investors and analysts to discuss and answer questions about the results at 8:00am Eastern Time on February 6, 2017. 

How To Play Trump - 6 Stocks For The Next 4 Years

2017-01-18 seekingalpha
Greenlight's (NASDAQ:GLRE) David Einhorn released his investor letter in which he lays out how to be well-positioned for the Trump presidency. That positioning contemplates new tax policies. Einhorn is long Apple (NASDAQ:AAPL) in part because the company could gain from tax reform and new policies around tax-efficient repatriation of foreign cash, of which Apple has a boatload. They have over $200 billion of such offshore cash that could return to the US during the Trump administration.

Mergers And Acquisitions In 2016: Pause For Breath In A Shifting Market

2017-01-18 seekingalpha
Are pharma groups biding their time or exercising caution? This is the question that needs to be asked when looking at 2016’s M&A totals, which fell back substantially from the free-spending days of 2014 and 2015.

What Does 3M's 2017 Look Like?

2017-01-18 seekingalpha
The beginning half of 2017 will likely be focused mostly on Trump's inauguration, the first 100 days, and whether all his business-friendly reforms happen as quickly as he says or if they take years (like many, including myself, think they will).

InVivo Therapeutics Release: Company Featured In Nationally Syndicated Radio Segment

2017-01-18 devicespace
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin was interviewed by Lisa Davis, M.P.H., C.N.C. for a segment on “It’s Your Health” radio during the annual J.P. Morgan Healthcare Conference.

Corindus Vascular Robotics Release: Company Announces Business Accomplishments For Fourth Quarter And Full Year 2016 And Updates 2017 Financial Guidance

2017-01-18 devicespace
WALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, announced today select business highlights from fourth quarter and full year 2016 and updated 2017 financial guidance. The Company will be hosting a conference call on Wednesday, January 18, 2017 at 8:00am ET to discuss these results and other recent achievements.

Biotech Industry Outperforming Markets in 2017: Latest Reports on Benitec Biopharma and Tandem Diabetes Care

2017-01-18 accesswire
NEW YORK, NY / ACCESSWIRE / January 18, 2017 / Biotech and Pharmaceutical companies took a hit last week after President Trump criticized the drug industry at a press conference.

Jazz Begins Phase III Study for Label Expansion of Defitelio

2017-01-18 zacks
Jazz Pharmaceuticals Public Limited Company (JAZZ - Free Report) announced the initiation of a phase III clinical study on its marketed drug, Defitelio (defibrotide), for the potential prevention of veno-occlusive disease (VOD) in high-risk adult and pediatric patients. Defitelio is currently available in the U.S. for the treatment of adult and pediatric patients with hepatic VOD with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT).

Sanofi Diabetes Drug Suliqua Wins EU Marketing Approval

2017-01-18 zacks
Sanofi (SNY - Free Report) announced that the European Commission has granted marketing authorization to its once-daily injection, Suliqua a combination of diabetes drugs Lantus and lixisenatide (EU trade name: Lyxumia) for the treatment of diabetes. The drug was approved in the EU in combination with metformin to improve glycemic control, which has not been provided by metformin alone or by a combination of metformin and another oral glucose-lowering medicinal product or basal insulin.

Zacks.com featured highlights: Glaukos, Apogee Enterprises, Braskem SA, Sundance Energy Australia and Angang Steel

2017-01-18 zacks
Chicago, IL – January 18, 2017 - Stocks in this week’s article include Glaukos Corporation (NYSE: (GKOS - Free Report) – Free Report ), Apogee Enterprises Inc. (NASDAQ: (APOG - Free Report) – Free Report ), Braskem SA (NYSE: (BAK - Free Report) – Free Report ), Sundance Energy Australia Limited (NASDAQ: (SNDE - Free Report) – Free Report ) and Angang Steel Company Limited (OTCMKTS: (ANGGY - Free Report) – Free Report ).

The Zacks Analyst Blog Highlights: Intuitive Surgical, Stryker and Hologic

2017-01-18 zacks
Chicago, IL – January 18, 2017, 2016 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Intuitive Surgical, Inc. (NASDAQ: (ISRG - Free Report) – Free Report ), Stryker Corporation (NYSE: (SYK - Free Report) – Free Report ) and Hologic, Inc.

Baxter (BAX): Sluggish Macro Environment Mars Prospects

2017-01-18 zacks
On Jan 17, we issued an updated research report on Deerfield, IL-based Baxter International Inc. (BAX - Free Report) , a global medical technology company and leading provider of renal and hospital products. An unfavorable estimate revision trend for the next year is a dampener for the stock at the moment. The stock currently carries a Zacks Rank #4 (Sell).

Stryker (SYK): Can It Post a Beat this Earnings Season?

2017-01-18 zacks
Stryker Corporation (SYK - Free Report) , a leading player in the medical technology space, is set to report fourth-quarter and full-year 2016 results on Jan 24 after the bell.

Is Earnings Beat Likely for Intuitive Surgical (ISRG) in Q4?

2017-01-18 zacks
We expect Intuitive Surgical Inc (ISRG - Free Report) to beat earnings expectations when it reports fourth-quarter 2016 and full-year results on Jan 24, after the closing bell. Last quarter, the company reported earnings of $5.39 per share, which exceeded the Zacks Consensus Estimate by $1.04. We note that on average, Intuitive Surgical posted a positive earnings surprise of 17.86% over the last four quarters.

Agenus, NCI Ink Deal to Evaluate Prophage-Keytruda Combo

2017-01-18 zacks
Agenus Inc. (AGEN - Free Report) announced that it has entered into a clinical trial collaboration with the National Cancer Institute (NCI) to evaluate its personalized autologous vaccine candidate, Prophage (HSPPC-96), in conjunction with Merck & Co., Inc.’s (MRK - Free Report) PD-1 therapy, Keytruda. A look at Agenus’ price movement in the past one year shows that the company has outperformed the Medical-Biomedical/Genetics industry, having increased 30.